Formulation-controlled redaporfin cellular-targeted photodynamic therapy sensitizes tumors to PD-1/PD-L1 blockade via immunogenic cell death.
Redaporfin is a clinically advanced photosensitizer developed for vascular-targeted photodynamic therapy (V-PDT), yet its therapeutic utility under long drug-to-light interval, cellular-targeted PDT (C-PDT), remains limited despite substantial tumor exposure. Here, we show that formulation-dependent control of redaporf...